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Proteostasis maintenance of -aminobutyric acid type A
(GABAA) receptors dictates their function in controlling neuro-
nal inhibition in mammalian central nervous systems. However,
as a multisubunit, multispan, integral membrane protein, even
wild type subunits of GABAA receptors fold and assemble inef-
ficiently in the endoplasmic reticulum (ER). Unassembled and
misfolded subunits undergo ER-associated degradation (ERAD), but
this degradation process remains poorly understood for GABAA
receptors. Here, using the 1 subunits of GABAA receptors as a
model substrate, we demonstrated that Grp94, a metazoan-spe-
cific Hsp90 in the ER lumen, uses its middle domain to interact
with the 1 subunits and positively regulates their ERAD. OS-9,
an ER-resident lectin, acts downstream of Grp94 to further rec-
ognize misfolded 1 subunits in a glycan-dependent manner.
This delivers misfolded 1 subunits to the Hrd1-mediated ubiq-
uitination and the valosin-containing protein-mediated extrac-
tion pathway. Repressing the initial ERAD recognition step by
inhibiting Grp94 enhances the functional surface expression of
misfolding-prone 1(A322D) subunits, which causes autosomal
dominant juvenile myoclonic epilepsy. This study clarifies a
Grp94-mediated ERAD pathway for GABAA receptors, which
provides a novel way to finely tune their function in physiologi-
cal and pathophysiological conditions.
Proteostasis maintenance of membrane proteins is essential
for their function in normal physiology (1– 4). Because of the
complex structure of membrane proteins, their folding and
assembly in the endoplasmic reticulum (ER)2 are often ineffi-
cient. Many pathogenic mutations aggravate such inefficient
processes. Misfolded and unassembled membrane proteins are
rapidly disposed via the ER-associated degradation (ERAD)
pathway (5– 8). Excessive ERAD is linked to an increasing
number of human diseases (9). The ER proteostasis network
regulates the protein folding, assembly, and degradation pro-
cesses. However, such processes and ER proteostasis net-
work components for integral membrane proteins remain
poorly understood.
We use -aminobutyric acid type A (GABAA) receptors as a
model to elucidate the ERAD pathway. GABAA receptors are
the primary inhibitory neurotransmitter-gated ion channels in
the mammalian central nervous system (10), belonging to the
Cys loop superfamily, which also includes nicotinic acetylcho-
line receptors (11, 12). Remarkably, under physiological condi-
tions only 20 –30% of newly synthesized wild type (WT) sub-
units of nicotinic acetylcholine receptors reach their intended
destination at the plasma membrane (13). This is likely the case
for GABAA receptors as well (14). Moreover, proteasome inhi-
bition substantially accumulates WT 1 subunits of GABAA
receptors in cells, supporting that they are an ERAD substrate
(15). Such an unproductive surface trafficking and extensive
ERAD is also observed for many other WT membrane proteins,
including cystic fibrosis transmembrane conductance regula-
tor (16, 17) and peripheral myelin protein 22 (18). In humans,
GABAA receptors have at least 19 subunits (1– 6, 1–3, 1–3,
, , , , 	1–3). The most common type in the human brain
contains two 1 subunits, two 2 subunits, and one 2 subunit.
Individual subunits need to fold into their native structures in
the ER (19, 20) and assemble with other subunits correctly on
the ER membrane to form a heteropentamer (14, 21, 22) for
subsequent trafficking to the plasma membrane. The recent
crystal structure of human 3 subunits confirms the long-pre-
dicted GABAA receptor subunit topology (23). Each subunit
has the following: a large extracellular (or ER luminal) N termi-
nus; four transmembrane (TM) helices (TM1–TM4, with the
TM2 domain lining the interior of the pore); a large intracellu-
lar loop connecting TM3 and TM4; and a short extracellular (or
ER luminal) C terminus (Fig. 1A). Loss of function of GABAA
receptors causes idiopathic epilepsies (24 –26) and many other
psychiatric and neurological disorders (27). Numerous muta-
tions in GABAA receptors predispose them to misfolding or
insufficient assembly and thus excessive ERAD (28, 29). For
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example, the missense A322D mutation in the TM3 domain of
the 1 subunit leads to its misfolding and thus loss of functional
channels on the plasma membrane (30), causing autosomal
dominant juvenile myoclonic epilepsy (31).
Cells use the ERAD pathway to recognize misfolded proteins
in the ER, dislocate them from the ER membrane, ubiquitinate
them using various ubiquitin E3 ligases, and target them for
degradation by cytosolic 26S proteasome (5, 6, 32–34). This
process is accomplished by the synchronized action of a series
of chaperones and ERAD factors in the ER and cytosol, which
are collectively called the ERAD machinery. Much of our
understanding about the basic principles of ERAD comes from
genetic and biochemical studies in yeast (8, 35), and recently,
more knowledge has been gained in mammalian cells (36). The
core ERAD machinery is well conserved from yeast to human,
although the ERAD system in mammalian cells is much more
complex. Here, we focused on elucidating the ERAD pathway of
GABAA receptors in HEK293 cells, which is largely unexplored.
We demonstrated that glucose-regulated protein 94 (Grp94)
and osteosarcoma amplified 9 (OS-9) recognize misfolded WT
1 subunits in the ER lumen and deliver them for ubiquitina-
tion by Hrd1 (gene name SYVN1).
Experimental Procedures
Chemicals and Plasmids—MG-132 was obtained from
Sigma. Eeyarestatin I came from Tocris Bioscience. BNIM, a
specific Grp94 inhibitor, was synthesized according to the pub-
lished procedure (37). Dithiobis(succinimidyl propionate)
(DSP) was obtained from Thermo Scientific. The pCMV6 plas-
mids containing the human GABAA receptor 1 (Uniprot no.
P14867-1), 2 (isoform 2, Uniprot no. P47870-1), and 2 (iso-
form 2, Uniprot no. P18507-2) subunits and pCMV6 Entry Vec-
tor plasmid (pCMV6-EV) were obtained from Origene. The
human GABAA receptor 1 subunit missense mutation A322D
or N38Q/N138Q was constructed using a QuickChange II site-
directed mutagenesis kit (Agilent Genomics). A FLAG tag was
inserted between Leu-31 and Gln-32 in the 1 subunit, which
did not interfere with its trafficking (38). The pCMV6-XL4
plasmid containing human Grp94 was obtained from Origene.
An HA tag was inserted between Ser-796 and Thr-797 in
Grp94, keeping the KDEL ER retention signal intact using the
QuickChange II site-directed mutagenesis kit (Agilent Geno-
mics). The forward and reverse primers for HA tag inserted are as
follows: forward (5 to 3), agatgaagaagaagaaacagcaaaggaatctt-
acccatacgatgttccagattacgctacagctgaaaaagatg, and reverse, catc-
tttttcagctgtagcgtaatctggaacatcgtatgggtaagattcctttgctgtttcttctt-
cttcatct. Grp94 variants were constructed by deletions of the
C-terminal domain (602–785 amino acids), N-terminal domain
(22–341 amino acids), MC domain (342–785 amino acids), N
and C domains (22–341 and 602–785 amino acids), and NM
domain (22– 601 amino acids) from the full-length HA-tagged
Grp94 plasmid using QuickChange II site-directed mutagene-
sis kit (Agilent Genomics). Primers for Grp94 mutants are listed
as follows: Grp94-N domain forward (5 to 3), gggaacttatga-
atgatatcaaaccaacagatgaagaagaagaaacagc, and reverse, gctgtttc-
ttcttcttcatctgttggtttgatatcattcataagttccc; Grp94-NM domain
forward (5 to 3), ccaaggaaggagtgaagttcgatgaaagtacagat-
gaagaagaagaaacagc, and reverse, gctgtttcttcttcttcatctgtactttcat-
cgaacttcactccttccttgg; Grp94-MC domain forward (5 to 3),
cgggtcggtcagagctatatggcagagaccat, and reverse, atggtctctgccat-
atagctctgaccgacccg; Grp94-C domain forward (5 to 3), cgg-
gtcggtcagagctgagaaaactaaggagag, and reverse, ctctccttagttttct-
cagctctgaccgacccg. The Grp94-M domain plasmid was con-
structed from the Grp94-MC domain plasmid using primers
for Grp94-NM domain. All cDNA sequences were confirmed
by DNA sequencing. The pcDNA3.1 plasmids containing
human WT Hrd1 and C291A Hrd1 are a gift from Professor
Ron Kopito (Stanford University). The GFP and pCS2-
mCherry and the pRK5-HA-ubiquitin-WT plasmids were
obtained from Addgene.
Antibodies—The mouse monoclonal anti-1 subunit anti-
body (clone BD24) was obtained from Millipore (catalogue no.
MAB339); the rabbit polyclonal anti-1 antibody was from
R&D Systems (catalogue no. PPS022), and the goat polyclonal
anti-1 subunit antibody (A-20) was from Santa Cruz Biotech-
nology (catalogue no. SC-31405). The mouse monoclonal anti-
-actin antibody came from Sigma (catalogue no. A1978). The
rabbit polyclonal anti-calnexin (catalogue no. ADI-SPA-860-F)
and rat polyclonal anti-Grp94 (catalogue no. ADI-SPA-850-F)
antibodies were from Enzo Life Sciences. The rabbit polyclonal
anti-Hrd1 (catalogue no. Ap2184e) and anti-HA tag (catalogue
no. Ap1012a) antibodies were obtained from Abgent. The rab-
bit monoclonal anti-OS-9 (catalogue no. 3705-1) and anti-VCP
(catalogue no. 3339-1) antibodies were obtained from Epito-
mics. The mouse monoclonal anti-His tag (catalogue no. 2366S)
and anti-ubiquitin (catalogue no. 3936) antibodies were
obtained from Cell Signaling. The rabbit monoclonal anti-so-
dium potassium ATPase (catalogue no. ab76020) antibody
came from Abcam. The mouse anti-gp78 (catalogue no.
SC-166358) antibody was obtained from Santa Cruz Biotech-
nology. The mouse anti-GST (catalogue no. NB600-446) anti-
body was obtained from Novus Biologicals.
Cell Culture and Transfection—HEK293 cells and SH-SY5Y
cells came from the ATCC and were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Hyclone) with 10% heat-
inactivated fetal bovine serum (Sigma) and 1% penicillin/
streptomycin (Hyclone) at 37 °C in 5% CO2. Monolayers were
passaged upon reaching confluency with TrypLE Express
(Invitrogen). Cells were grown in 6-well plates or 10-cm dishes
and allowed to reach 70% confluency before transient trans-
fection using FuGENE 6 (Roche Applied Science) or Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Stable cell lines for 122 and 1(A322D)22
receptors were generated using the G-418 selection method.
Briefly, cells were transfected with 1:2:2 (1:1:1) or 1-
(A322D):2:2 (1:1:1) plasmids and then maintained in
DMEM supplemented with 0.6 mg/ml G418 (Enzo Life Sci-
ences) for 15 days. G-418-resistant cells were selected for
follow-up experiments.
To generate monoclonal HEK293 cells stably expressing
1(A322D)22 receptors, the 1(A322D) sequence was sub-
cloned into a pIRES2-EGFP bicistronic vector (Clontech) using
EcoRI and SacII restriction sites, which would allow the simul-
taneous expression of 1 subunits and enhanced GFP sepa-
rately but from the same RNA transcript. After transfection and
G-418 treatment, cells that are GFP-positive were considered as
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those successfully transfected with the 1(A322D) subunit.
GFP-positive cells were further diluted into 96-well plates,
allowing a single cell distribution in each well. Cells with robust
GFP signals were further selected to grow to population.
Stable shGrp94 and shControl HEK293T cells were a kind
gift of Professor Yair Argon (University of Pennsylvania) (39).
They were maintained in DMEM with 10% heat-inactivated
fetal bovine serum (Sigma) and 1% penicillin/streptomycin
(Hyclone) at 37 °C in 5% CO2. Two 
g/ml puromycin (Dot Sci-
entific) was added to maintain the colony.
siRNA Transfection—HEK293 cells were seeded at 2.5 
105 cells per well in 6-well plates for the siRNA treatment. Cells
were allowed to reach 70% confluency before transfection.
The following small interfering RNA (siRNA) duplexes were
obtained from Dharmacon: Grp94 (J-006417-08); Hrd1 (J-
007090-08); gp78 (J-006522-08); OS-9 (J-010811-09); and non-
targeting siRNA D-001810-01-20), which was used as a nega-
tive control. Cells were transfected with corresponding 50 nM
siRNA using the HiPerfect transfection reagent (Qiagen)
according to the manufacturer’s transfection protocol. Forty
eight hours post-transfection, cells were harvested for further
analysis.
Western Blot Analysis—Cells were harvested with TrypLE
Express and then lysed with lysis buffer (50 mM Tris, pH 7.5, 150
mM NaCl, and 1% Triton X-100) supplemented with the Roche
Applied Science complete protease inhibitor mixture. Lysates
were cleared by centrifugation (15,000  g, 10 min, 4 °C). Pro-
tein concentration was determined by MicroBCA assay
(Pierce). Aliquots of cell lysates were separated in an SDS-8%
polyacrylamide gel, and Western blot analysis was performed
using the appropriate antibodies. Band intensity was quantified
using ImageJ software from the National Institutes of Health.
Quantitative RT-PCR—The relative expression levels of tar-
get genes were analyzed using quantitative RT-PCR. Total RNA
was extracted from cells using the RNeasy mini kit (Qiagen
catalogue no. 74104). cDNA was synthesized from 500 ng of
total RNA using the QuantiTect reverse transcription kit (Qia-
gen catalogue no. 205311). Quantitative PCRs (40 cycles of 15 s
at 94 °C, 30 s at 57 °C, and 30 s at 72 °C) were performed using
cDNA, the QuantiTect SYBR Green PCR kit (Qiagen catalogue
no. 204143), and corresponding primers in the StepOnePlus
system (Applied Biosystems). The results were analyzed using
StepOne version 2.2 software (Applied Biosystems). The for-
ward and reverse primers for CHOP are 5-GGAAACAGAG-
TGGTCATTCCC-3 and 5-CTGCTTGAGCCGTTCATT-
CTC-3; the forward and reverse primers for Grp94 are 5-
GGCCAGTTTGGTGTCGGTTT-3 and 5-CGTTCCCCGT-
CCTAGAGTGTT-3; the forward and reverse primers for
GAPDH (housekeeping gene control) are 5-GTCGGAGTCA-
ACGGATT-3 and 5-AAGCTTCCCGTTCTCAG-3. The
threshold cycle (CT) was extracted from the PCR amplification
plot, and the CT value was defined as follows: CT  CT (tar-
get gene)  CT (housekeeping gene). The relative mRNA
expression level of target genes of treated cells was normalized
to that of control cells as follows: relative mRNA expression
level  2 exp((CT (treated cells)  CT (control cells))).
Each data point was evaluated in triplicate and measured using
two biological replicates.
Cycloheximide (CHX) Chase Assay—HEK293 cells were
seeded at 2.5  105 cells per well in 6-well plates and incubated
at 37 °C overnight. Cells were then transfected with the indi-
cated siRNAs or plasmids for 48 h prior to CHX chase. To stop
protein translation, cells were treated with 100 
g/ml CHX
(Amresco). Cells were then chased for the indicated time, har-
vested, and lysed for SDS-PAGE and Western blot analysis.
Biotinylation of Cell Surface Proteins—HEK293 cells and
SH-SY5Y cells stably overexpressing 122 or 1(A322D)22
receptors were plated in 10-cm dishes for surface biotinylation
experiments according to our published procedure (40). Briefly,
intact cells were washed twice with ice-cold PBS and incubated
with the membrane-impermeable biotinylation reagent Sulfo-
NHS SS-Biotin (0.5 mg/ml; Pierce) in PBS containing 0.1 mM
CaCl2 and 1 mM MgCl2 (PBS  CM) for 30 min at 4 °C to label
surface membrane proteins. To quench the reaction, cells were
incubated with 10 mM glycine in ice-cold PBS  CM twice for 5
min at 4 °C. Sulfhydryl groups were blocked by incubating the
cells with 5 nM N-ethylmaleimide in PBS for 15 min at room
temperature. Cells were solubilized for 1 h at 4 °C in lysis buffer
(1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, and 5 mM
EDTA, pH 7.5) supplemented with the complete protease
inhibitor mixture (Roche Applied Science) and 5 mM N-ethyl-
maleimide. The lysates were cleared by centrifugation
(16,000  g, 10 min at 4 °C) to pellet cellular debris. The super-
natant contained the biotinylated surface proteins. The con-
centration of the supernatant was measured using MicroBCA
assay (Pierce). Biotinylated surface proteins were affinity-puri-
fied from the above supernatant by incubating for 1 h at 4 °C
with 100 
l of immobilized neutravidin-conjugated agarose
bead slurry (Pierce). The samples were then subjected to cen-
trifugation (16,000  g, 10 min, at 4 °C). The beads were washed
six times with buffer (0.5% Triton X-100, 50 mM Tris-HCl, 150
mM NaCl, and 5 mM EDTA, pH 7.5). Surface proteins were
eluted from beads by boiling for 5 min with 200 
l of LSB/urea
buffer (2 Laemmli sample buffer (LSB) with 100 mM DTT and
6 M urea, pH 6.8) for SDS-PAGE and Western blotting analysis.
The Na/K-ATPase  chain serves as a loading control for
biotinylated membrane proteins.
Immunoprecipitation—For immunoprecipitation using cell
lysates (500 
g), they were pre-cleared with 30 
l of protein
A/G plus-agarose beads (Santa Cruz Biotechnology) and 1.0 
g
of normal mouse IgG for 1 h at 4 °C to remove nonspecific
binding proteins. The pre-cleared cell lysates were incubated
with 2.0 
g of mouse anti-1 antibody (clone BD24) for 1 h at
4 °C and then with 30 
l of protein A/G plus agarose beads
overnight at 4 °C. For immunoprecipitation using the mouse
brain homogenates (1 mg), they were pre-cleared with 30 
l of
protein A/G plus-agarose beads (Santa Cruz Biotechnology)
and 1.0 
g of normal rat IgG for 1 h at 4 °C to remove nonspe-
cific binding proteins. The pre-cleared complex was incubated
with 2.0 
g of rat anti-Grp94 antibody for 1 h at 4 °C and then
with 30 
l of protein A/G plus agarose beads overnight at 4 °C.
Afterward, the beads were collected by centrifugation at 8000 
g for 30 s and washed three times with lysis buffer. The complex
was eluted by incubation with 30 
l of SDS loading buffer in the
presence of DTT. The immunopurified eluents were separated
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in SDS-8% polyacrylamide gel, and Western blot analysis was
performed using appropriate antibodies.
HEK293 cells stably expressing (FLAG-1)22 GABAA
receptors were transfected with the indicated siRNA or plas-
mids for 48 h. Then Triton X-100 cell extracts (500 
g) were
pre-cleared with 30 
l of protein A/G plus-agarose beads
(Santa Cruz Biotechnology) and 1.0 
g of normal mouse IgG
for 1 h at 4 °C to remove nonspecific binding proteins. The
pre-cleared cell lysates were incubated with anti-FLAG M2
magnetic beads (Sigma) for 1 h at room temperature. After-
ward, the beads were collected by a magnetic separator (Pro-
mega) and washed three times with lysis buffer. The complex
was eluted by incubation with 30 
l of FLAG peptides (1
mg/ml) or SDS loading buffer in the presence of DTT. The
immunopurified eluents were separated in SDS-8% polyacryl-
amide gel, and Western blot analysis was performed using
appropriate antibodies.
The cross-linking reaction was carried out as before with
modification (41). Cells in 10-cm dishes were treated with 10

M proteasome inhibitor MG-132 for 2 h before harvesting.
Cells were then washed with DPBS and cross-linked by incuba-
tion with 1.5 mM dithiobis(succinimidyl propionate) (DSP) in
DPBS for 15 min at room temperature. The DSP reaction was
quenched by the addition of 10 mM Tris buffer, pH 7.5. Cells
were then scraped into microtubes, pelleted, and washed with
DPBS. Then cells were lysed in the Triton X-100 lysis buffer,
and the total cell lysates were immunoprecipitated with a
mouse anti-1 antibody or anti-FLAG M2 magnetic beads. The
immunoisolated eluents were blotted with rabbit anti-OS-9
and rabbit anti-1 subunit antibodies.
In Vivo Ubiquitination Assay—HEK293 cells stably express-
ing (FLAG-1)22 GABAA receptors were transfected with
HA-tagged ubiquitin constructs together with the indicated
siRNAs or plasmids. Two hours before harvesting cells, 10 
M
proteasome inhibitor MG-132 was added. Forty eight hours
post-transfection, Triton X-100 cell extracts (500 
g) were
immunoprecipitated with anti-FLAG M2 magnetic beads, and
the immunoisolated eluents were subjected to SDS-PAGE and
blotted with a mouse anti-ubiquitin antibody.
In Vitro Binding Assay—One 
g of GST epitope tag protein
(GST) (Novus Biologicals, catalogue no. NBC1-18537) or GST-
tagged GABAA receptor 1 subunit protein (GST-1) (Abnova,
catalogue no. H00002554-P01) was mixed with 4 
g of recom-
binant His-tagged Grp94 (ProSpec, catalogue no. hsp-091) pro-
tein in 500 
l of buffer (50 mM Tris, pH 7.5, 150 mM NaCl, and
1% Triton X-100). The protein complex was isolated by immu-
noprecipitation using anti-His antibody followed by SDS-
PAGE and Western blot analysis with a rabbit anti-GABAAR 1
subunit antibody (R&D Systems PPS022) or a mouse anti-GST
(Novus Biologicals NB600-446) antibody.
Mouse Brain Homogenization—C57BL/6J mice (The Jackson
Laboratory) at 6 –10 weeks were sacrificed, and the cortex was
isolated and homogenized in lysis buffer (25 mM Tris, pH 7.6,
150 mM NaCl, 1 mM EDTA, and 2% Triton X-100) supple-
mented with the complete protease inhibitor mixture from
Roche Applied Science. The sample was centrifuged at 800  g
for 10 min at 4 °C. The pellet was re-homogenized in the same
lysis buffer and centrifuged at 800  g for 10 min at 4 °C. The
combined supernatants were placed on a rotating device for 2 h
at 4 °C and then centrifuged at 15,000  g for 30 min at 4 °C.
The resulting supernatant was collected as mouse brain homo-
genate, and its protein concentration was determined by a
MicroBCA assay (Pierce). This animal study followed the
guidelines of the Institutional Animal Care and Use Commit-
tees (IACUC) at Case Western Reserve University and was car-
ried out in agreement with the recommendation of the Ameri-
can Veterinary Medical Association Panel on Euthanasia.
Whole-cell Patch Clamp Electrophysiology Recording—Whole-
cell currents were recorded using monoclonal HEK293 cells
stably expressing 1(A322D)22 receptors. The glass elec-
trodes were pulled from thin-walled borosilicate capillary glass
(Kimble-Chase) and fire-polished on a DMZ Universal puller
(Zeitz Instruments), having a tip resistance of 3–5 megohms.
The internal solution contained 153 mM KCl, 1 mM MgCl2,
5 mM EGTA, 10 mM HEPES, and 2 mM MgATP, pH 7.3. The
external solution contained 142 mM NaCl, 8 mM KCl, 6 mM
MgCl2, 1 mM CaCl2, 10 mM glucose, 10 mM HEPES, and 120 nM
fenvalerate, pH 7.4. Coverslips containing HEK293 cells were
placed in an RC-25 recording chamber (Warner Instruments)
on the stage of an Olympus IX-71 inverted fluorescence micro-
scope and superfused with external solution. Fast GABA appli-
cation was accomplished with a pressure-controlled perfusion
system (Warner Instruments) positioned within 50 
m of the
cell utilizing a Quartz MicroManifold with 100-
m inner diam-
eter inlet tubes (ALA Scientific). The whole-cell GABA-in-
duced currents were recorded at a holding potential of 60 mV
in voltage clamp mode using an Axopatch 200B amplifier
(Molecular Devices). The signals were filtered at 2 kHz and
detected at 10 kHz using pClamp10 acquisition software.
Statistical Analysis—All data are presented as mean 	 S.E.,
and any statistical significance was calculated using two-tailed
Student’s t test.
Results
Grp94 Positively Regulates the ERAD of the 1 Subunit of
GABAA Receptors—Grp94, a metazoan-specific member of the
Hsp90 family in the ER lumen, plays an important role in the
recognition of the following two ERAD substrates: mutant
1-antitrypsin (42, 43) and mutant myocilin (44). Probably a
more prominent role of Grp94 is to assist the folding of a very
limited subset of client proteins, including immunoglobulins
(45), multiple Toll-like receptors and integrins (46, 47), insulin-
like growth factors (48), and low density lipoprotein receptor-
related protein 6 (LRP6) (49). Therefore, we began to clarify
whether Grp94 promotes the folding or degradation of the WT
1 subunit of GABAA receptors. Transient knockdown of
Grp94 using small interfering RNA (siRNA) (49% knockdown
efficiency) significantly increased the total 1 subunit protein
level in HEK293 cells stably expressing WT 122 GABAA
receptors (Fig. 1B). This suggested a possible role of Grp94 in
positively regulating the ERAD of 1 subunits. Furthermore,
stable depletion of Grp94 using shRNA (
95% knockdown effi-
ciency) in HEK293T cells resulted in a more dramatic increase
of the steady state level of the 1 subunit (Fig. 1C), indicating
that the effect of Grp94 on the 1 subunit does not depend on
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FIGURE 1. Grp94 positively regulates the ERAD of the 1 subunit of GABAA receptors. A, subunit topology of GABAA receptors. The schematic is built from the
crystal structure of the 3 subunit (Protein Data Bank code 4COF). It has a large extracellular (or ER luminal) N terminus, four transmembrane (TM) helices (TM1–TM4),
a large intracellular loop connecting TM3 and TM4, and a short extracellular (or ER luminal) C terminus. The two cysteines that form the signature disulfide bond are
shown as sphere models. B, knocking down Grp94 increases the total and cell surface protein levels of WT 1 subunits. HEK293 cells stably expressing 122 GABAA
receptors were transfected with non-targeting (NT) control siRNA or siRNA against Grp94. Forty eight hours post-siRNA transfection, cells were lysed, and the total cell
lysates were subjected to SDS-PAGE and immunoblotting (IB) with mouse anti-1 or rat anti-Grp94 antibodies (n  3). -Actin serves as a total protein loading control.
Alternatively, the surface 1 subunits were measured using a cell surface protein biotinylation assay (n 3). The Na/K-ATPase  chain serves as a loading control for
biotinylated membrane proteins. Protein band quantifications using ImageJ are shown on the bottom panel. C, stably depleting Grp94 increases the total and cell
surface protein levels of WT 1 subunits. HEK293T cells stably expressing control (Ctr) or Grp94 shRNA were transiently transfected with WT 1 plasmids together with
2 and 2 subunit plasmids. Forty eight hours post-transfection, cells were lysed and treated as in B (n  3). D, Grp94 knockdown does not significantly influence the
mRNA level of CHOP by using quantitative RT-PCR analysis. HEK293 cells stably expressing 122 GABAA receptors were transfected with non-targeting control
siRNA or siRNA against Grp94 for 48 h, or cells were treated with thapsigargin (1 
M, 6 h) as a positive control, which induces CHOP mRNA expression. Then total RNA
was extracted from the cells and reverse-transcribed to cDNA before being subjected to quantitative PCR analysis. The experiments were done using two biological
replicates in triplicate each time. NS, not significantly. E, knocking down Grp94 increases the half-life of the 1 subunit determined by CHX chase analysis. HEK293 cells
stably expressing 122 GABAA receptors were transfected with non-targeting control siRNA or siRNA against Grp94 for 48 h and then chased for the indicated time
with CHX (100 
g/ml), which inhibits protein synthesis. Cells were lysed and subjected to SDS-PAGE and immunoblotting analysis (n  3). Degradation kinetics was
plotted by quantifying 1 intensity against time after CHX addition on the bottom panel. F, stably depleting Grp94 increases the half-life of the 1 subunit determined
by CHX chase analysis. HEK293T cells stably expressing control (Ctr) or Grp94 shRNA were transiently transfected with WT1 plasmids together with2 and2 subunit
plasmids for 48 h and then chased for the indicated time with CHX (100 
g/ml). Cells were then treated as in E (n 3). G, overexpression of HA-tagged Grp94 decreases
the half-life of the 1 subunit determined by CHX chase analysis. HEK293 cells stably expressing 122 GABAA receptors were transfected with empty vector (EV)
controls or HA-tagged Grp94 plasmids for 48 h and then chased with CHX (100 
g/ml) for the indicated time (n  3). H, Grp94 knockdown decreases the relative
ubiquitination level of 1 subunits. HEK293 cells stably expressing (FLAG-1)22 GABAA receptors were transfected with an HA-tagged ubiquitin plasmid together
with non-targeting control siRNA or siRNA against Grp94 for 48 h. Total cell lysates were then immunoprecipitated with anti-FLAG M2 magnetic beads before being
subjected to SDS-PAGE and blotted for ubiquitin. Quantification of the ratio of ubiquitin/1 band intensity post-immunoprecipitation, representing the relative
ubiquitin level of the 1 subunits, is shown on the bottom (n  3). IB, immunoblotting. IP, immunoprecipitation. Each data point in B–H is reported as mean 	 S.E. *,
p  0.05.
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whether the depletion of Grp94 is short term or long term (also
see under “Discussion”).
Quantitative RT-PCR analysis showed that reducing the
Grp94 level genetically did not significantly increase the mRNA
level of CHOP, a pro-apoptotic marker, indicating that this
operation did not cause cell toxicity (Fig. 1D). Also, it has been
reported that silencing Grp94 only induces the expression of a
limited set of proteostasis network components, which is dis-
tinct from activating the unfolded protein response (39). In
response to misfolded proteins in the ER, the unfolded protein
response adjusts the cellular proteostasis by translational atten-
uation and transcriptional remodeling of the ER proteostasis
network, including some ERAD components (50, 51). There-
fore, it is unlikely that Grp94 acts as a general ERAD substrate-
recruiting chaperone.
We next manipulated the Grp94 level genetically and evalu-
ated the influence on the degradation rate of 1 subunits using
the CHX chase assay. The 1 subunit has a half-life of 1.6 h
when fitted to a single exponential function (Fig. 1E). Remark-
ably, transiently depleting Grp94 using siRNA substantially
increased its half-life to 3.5 h (Fig. 1E), indicating that Grp94
positively regulates the 1 subunit degradation. Consistently,
permanent inactivation of Grp94 reduced the degradation rate
of the 1 subunit (Fig. 1F), and overexpression of HA-tagged
Grp94 significantly decreased the half-life of the 1 subunit to
0.8 h (Fig. 1G).
Moreover, we determined the effect of Grp94 in regulating
the ubiquitination of the 1 subunit. HEK293 cells expressing
FLAG-122 GABAA receptors were transfected with HA-
tagged ubiquitin, immunoprecipitated with anti-FLAG mag-
netic beads, and blotted for ubiquitin. The ratio of ubiquitin to
1 subunit post-immunoprecipitation represents the relative
ubiquitination level of the 1 subunit. This in vivo ubiquitina-
tion assay clearly demonstrated that knockdown of Grp94 (55%
knockdown efficiency) decreased the relative ubiquitination
level of the 1 subunit (Fig. 1H), indicating that Grp94 posi-
tively regulates the ubiquitination and ERAD of the 1 subunit.
As a result, transiently or stably depleting Grp94 significantly
increased the surface 1 subunit protein level using a cell sur-
face biotinylation assay (Fig. 1, B and C).
Grp94 Uses Its Middle Domain to Bind the 1 Subunit of
GABAA Receptors—Because operating Grp94 genetically could
influence the ER proteostasis network, we asked whether
Grp94 directly binds the 1 subunit. We carried out an in vitro
binding assay using recombinant GST-tagged 1 subunits and
recombinant His-tagged Grp94 proteins. The His tag antibody
pulldown led to the detection of the 1 subunit in the GST-1
complex using an anti-1 antibody or an anti-GST antibody,
although we did not detect any 1 band in the GST control
complex (Fig. 2A), indicating that Grp94 directly binds the 1
subunit. However, because the folding degree of the recombi-
nant 1 subunit was not characterized, whether such an inter-
action is functionally relevant to its ERAD remains to be estab-
lished. To show an endogenous interaction between Grp94 and
the 1 subunit in the mammalian central nervous systems, we
performed a co-immunoprecipitation assay using the mouse
brain cortex homogenates. Pulling down Grp94 led to the
detection of the 1 subunit (Fig. 2B), confirming an endoge-
nous interaction between Grp94 and the 1 subunit.
We next characterized the cellular interaction between
Grp94 and the 1 subunit. FLAG-tagged 1 subunits strongly
interacted with endogenous Grp94 in HEK293 cells (Fig. 1H).
Grp94 is divided into three domains as follows: an N-terminal
domain containing an ATP-binding site (N domain), a middle
domain (M domain), and a C-terminal domain containing
dimerization sites (C domain) (52). The specific domain that
Grp94 uses to interact with its substrates may vary for different
substrates. For example, it was reported that Grp94 uses its
C-terminal domain to bind Toll-like receptors (53) but uses its
M domain to interact with OS-9 (54). To determine which
domain of Grp94 interacts with the 1 subunit in the ER lumen,
we constructed plasmids containing an HA-tagged full-length
N domain, M domain, C domain, NM domain, or MC domain
of Grp94 (Fig. 2C). HEK293 cells expressing (FLAG-1)22
GABAA receptors were transiently transfected with these HA-
tagged Grp94 variant plasmids for 48 h before being immuno-
precipitated using an anti-FLAG antibody and blotted for HA.
Clearly, the M domain, but not the N domain or the C domain,
was pulled down with the 1 subunit (Fig. 2D, cf. lanes 13 to 12
and 14), indicating that the M domain alone is sufficient to bind
the 1 subunit. The M construct migrated as two bands in the
SDS-polyacrylamide gel; the lower band corresponds to the
molecular weight of a monomer, and the upper band corre-
sponds to that of a dimer, which was resistant to the SDS dena-
turation (Fig. 2D, lane 6). Only the fast migrating M species
interacted with the 1 subunit (Fig. 2D, lane 13), possibly
because the putative dimerization of the M domain prevented
its association with the 1 subunit. Intriguingly, the 1 subunit
interacted with the M domain and the MC domain much stron-
ger than the full-length Grp94 (Fig. 2D, cf. lanes 11 and 13 to 9).
However, the NM domain was not pulled down with the 1
subunit (Fig. 2D, lane 10), which could be due to the possibili-
ties that the addition of the N domain to the M domain blocked
the interaction between the M domain and the 1 subunit or
altered the conformation of the M domain.
OS-9 Acts Downstream of Grp94 to Recognize Misfolded 1
Subunits of GABAA Receptors through a Glycan-dependent
Manner—The 1 subunit has two N-linked glycosylation sites,
Asn-38 and Asn-138. The oligosaccharyltransferase complex
catalyzes this glycosylation and transfers 14-monosaccharide
residues Glc3Man9GlcNAc2 to an Asn residue contained in an
Asn-Xaa-(Ser/Thr) sequence motif (Xaa can be any residue
except Pro). N-Glycans serve as sensors of glycoprotein folding
in the ER (55, 56). The recognition of terminally misfolded
N-linked glycoproteins is mediated by mannose trimming
events, which are facilitated by ER-mannosidase I and EDEM
proteins after the release of glycoproteins from the calnexin/
calreticulin cycles (57, 58). Afterward, two ER-resident lectins,
OS-9 and XTP3-B, recognize the trimmed oligosaccharides
(42). OS-9 and XTP3-B seem to have distinct sets of substrates.
OS-9, but not XTP3-B, robustly binds Grp94 (42). Therefore, it
is possible the Grp94-mediated ERAD substrates depend on
OS-9. Because Grp94 positively regulates the ERAD of the 1
subunit, we next determined the role of OS-9 in this degrada-
tion process and the potential sequential effect of OS-9 with
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Grp94. Knockdown of OS-9 (71% knockdown efficiency) signif-
icantly increased the total 1 subunit protein level 3.0-fold (Fig.
3A), supporting that OS-9 recognizes the misfolded 1 subunit
for ERAD. To access the role of N-glycans in the function of
OS-9, we introduced the N38Q/N138Q double mutation at
both glycosylation sites (Asn-38 and Asn-138) in the 1 sub-
unit. This QQ mutation reduced the mass and protein level of
the 1 subunit (Fig. 3B, cf. 2nd to 1st lane and 6th to 5th lane),
indicating that glycosylation is required for the maturation
of this subunit. A co-immunoprecipitation assay revealed
that the QQ mutation significantly decreased the interaction
between OS-9 and the 1 subunit according to the quantifica-
tion of the ratio of OS-9 to 1 after immunoprecipitation using
anti-1 antibody in HEK293 cells (Fig. 3B, cf. 6th to 5th lane).
This indicates that OS-9 binds the N-glycans in the 1 subunit.
The above data (Fig. 3, A and B) supported the assertion that
OS-9 recognizes misfolded 1 subunit in a glycan-dependent
manner.
We next determined the sequential interactions of calnexin,
Grp94, and OS-9 with the 1 subunit during its biogenesis
pathway. We began to evaluate the binding sequence of Grp94
and OS-9 with the 1 subunit. Knocking down Grp94 de-
creased the interaction between the 1 subunit and OS-9 sig-
nificantly (Fig. 3C, cf. 6th to 5th lane), and consistently deplet-
ing OS-9 increased the interaction between the 1 subunit and
Grp94 significantly in HEK293 cells (Fig. 3D), indicating that
Grp94 acts upstream of OS-9 during the recognition of mis-
folded 1 subunits. Previously, we reported that calnexin binds
the 1 subunits through the glycans and promotes their matu-
ration (40). If the 1 subunits that exit the calnexin cycle fail to
fold into their native structures, they are likely the substrate of
Grp94. To determine whether Grp94 functions downstream of
calnexin, we carried out a co-immunoprecipitation assay.
Knockdown of Grp94 significantly increased the interaction
between the 1 subunit and calnexin in HEK293 cells express-
ing 122 receptors (Fig. 3E), indicating that Grp94 acts
downstream of calnexin and accepts misfolded 1 subunits
after they depart from calnexin. Afterward, Grp94 delivers the
substrate to OS-9 for processing, and then the substrate will be
further tagged by ubiquitin for degradation.
FIGURE 2. Grp94 uses its middle domain to bind the 1 subunit of GABAA receptors. A, recombinant His-tagged Grp94 binds the recombinant GST-tagged
1 subunit of GABAA receptors in vitro. One 
g of GST or GST-1 was mixed with 4 
g of His-Grp94 in buffers containing 1% Triton X-100. The protein complex
was isolated by immunoprecipitation using an anti-His antibody, and the immunopurified eluents were separated by SDS-PAGE and blotted with a rabbit
anti-GABAAR 1 subunit antibody and a mouse anti-GST antibody (n  4). B, endogenous Grp94 binds the endogenous 1 subunit of GABAA receptors in the
mouse brain. Total lysates from the cortex of mouse brains were used for immunoprecipitation with a rat anti-Grp94 antibody or control rat IgG, and the
immunoisolated eluents were subjected to SDS-PAGE and Western blot analysis with rat anti-Grp94 and goat anti-1 antibodies (n  2). C, schematic
representation of HA-tagged Grp94 constructs. Full-length Grp94 contains a signal peptide (SP, residues 1–21), an N-terminal domain (N, residues 22–341), a
middle domain (M, residues 342– 601), and a C-terminal domain (C, 602–785). All constructs contain a signal peptide (residues 1–21), an HA tag that was
inserted between residues 796 and 797, and a sequence containing KDEL for ER localization (786 – 803). FL, full-length, 1– 803. NM, N and M domains, 1– 601 and
786 – 803. MC, M and C domains, 1–21 and 342– 803. N, N domain, 1–341 and 786 – 803. M, M domain, 1–21, 342– 601, and 786 – 803. C, C domain, 1–21 and
602– 803. D, interaction between different Grp94 domains and the 1 subunit. HEK293 cells stably expressing (FLAG-1)22 GABAA receptors and empty
vector-transfected HEK293 cells were transiently transfected with different HA-tagged variant Grp94 plasmids for 48 h. Then Triton X-100 cell extracts were
immunoprecipitated with anti-FLAG M2 magnetic beads, and the immunoisolated eluents were subjected to SDS-PAGE and blotted with rabbit anti-HA and
rabbit anti-1 subunit antibodies (n  2). EV, empty vector. IB, immunoblotting. IP, immunoprecipitation.
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Hrd1 Ubiquitinates the 1 Subunit of GABAA Receptors—
The mammalian ERAD systems are organized primarily by two
E3 ubiquitin ligases, Hrd1 and gp78 (36), and additional ubiq-
uitin ligases contribute to the degradation of a limited amount
of substrates. Hrd1 and gp78 are both homologous to Hrd1p, an
essential E3 ligase in yeast (59), but Hrd1 and gp78 have largely
FIGURE 3. OS-9 acts downstream of Grp94 to promote ERAD of the 1 subunit of GABAA receptors. A, OS-9 knockdown increases the total protein level
of WT 1 subunits. HEK293 cells stably expressing 122 GABAA receptors were transfected with non-targeting (NT) control siRNA or siRNA against OS-9.
Forty eight hours post-siRNA transfection, cells were lysed, and the total cell lysates were subjected to SDS-PAGE and immunoblotting with mouse anti-1 or
rabbit anti-OS-9 antibodies (n  3). -Actin serves as a protein loading control. Quantification of the total protein level of 1 is shown on the bottom. B, OS-9
interacts with the 1 subunit in a glycan-dependent way. The 1 subunit has two N-linked glycosylation sites at Asn-38 and Asn-138. The N38Q/N138Q double
mutations in the 1 subunit disrupt both glycosylation sites. HEK293 cells were transiently transfected with WT 1 or N38Q/N138Q 1 plasmids (together with
2 and 2 subunit plasmids). Cells were treated with 10 
M proteasome inhibitor MG-132 for 2 h before harvesting. Forty eight hours post-transfection, cells
were washed with DPBS and cross-linked by incubation with 1.5 mM DSP for 15 min at room temperature. DSP was quenched by the addition of 10 mM Tris
buffer, pH 7.5. Then cells were lysed, and the total cell lysates were immunoprecipitated with a mouse anti-1 antibody, and the immunoisolated eluents were
blotted with rabbit anti-OS-9 and rabbit anti-1 subunit antibodies (n  4). IgG was included as a negative control for immunoprecipitation. Quantification of
the intensity of OS-9/1 subunit post-IP represents the relative interaction between OS-9 and the 1 subunit and is shown on the bottom. The QQ mutation
reduces the mass of the 1 subunit (cf. 4th to 3rd lane). Consequently, it leads to significantly weaker interactions between the 1 subunit and OS-9. C, Grp94
knockdown decreases the interaction between OS-9 and the 1 subunit. HEK293 cells stably expressing (FLAG-1)22 GABAA receptors were transfected
with non-targeting control siRNA or siRNA against Grp94. Cells were treated with MG-132 (10 
M, 2 h) before harvesting. Forty eight hours post-transfection,
cells were cross-linked with DSP and lysed. Then Triton X-100 cell extracts were immunoprecipitated with anti-FLAG M2 magnetic beads, and the immuno-
isolated eluents were blotted with rabbit anti-OS-9 and rabbit anti-1 subunit antibodies (n  4). Quantification of the relative intensity of OS-9/1 post-IP is
shown on the bottom. D, OS-9 knockdown, MG-132 treatment, or EER1 treatment enhances the interaction between the 1 subunit and Grp94. HEK293 cells
stably expressing 122 GABAA receptors were transfected with non-targeting siRNA and siRNA against Grp94 for 48 h or treated with MG-132 (2 
M, 6 h), a
potent proteasome inhibitor, and eeyarestatin I (EER1) (5 
M, 24 h), a potent VCP inhibitor. The cell lysates were then subjected to immunoprecipitation before
SDS-PAGE and Western blot analysis with rat anti-Grp94 and rabbit anti-1 antibodies (n  3). Quantification of the intensity of Grp94/1 subunit post-IP
represents their relative interaction and is shown on the bottom. E, Grp94 knockdown enhances the interaction between the 1 subunit and calnexin. HEK293
cells stably expressing 122 GABAA receptors were transfected with non-targeting control siRNA or siRNA against Grp94 for 48 h. Then Triton X-100 cell
extracts were immunoprecipitated with a mouse anti-1 antibody, and the immunoisolated eluents were blotted with rabbit anti-calnexin (CNX) and rabbit
anti-1 subunit antibodies (n  3). Quantification of the relative intensity of calnexin/1 post-IP is shown on the bottom. Each data point is reported as mean 	
S.E. *, p  0.05. IB, immunoblot.
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distinct interaction networks (36). Moreover, gp78 acts down-
stream of Hrd1 to enhance the ERAD of a model luminal sub-
strate, a truncated major histocompatibility complex class I
heavy chain molecule (MHC-1–147) (60). We evaluated the
role of Hrd1 and gp78 in degrading the 1 subunit. Knockdown
of Hrd1 using siRNA increased the total protein level of the 1
subunit in HEK293 cells stably expressing 122 GABAA
receptors (Fig. 4, A and B), whereas knockdown of gp78 did not
(Fig. 4C), indicating that Hrd1, but not gp78, plays an essential
role for this ERAD substrate. Consistently, overexpression of
Hrd1 substantially decreased the total protein level of the 1
subunit (Fig. 4, D and E). Moreover, we utilized a C291A muta-
tion, which resides in the critical RING domain in Hrd1, exhib-
iting a dominant negative effect on its ubiquitin ligase activity
(61). As a result, overexpression of C291A Hrd1 significantly
increased the total 1 subunit level (Fig. 4, D and E). We next
employed the cycloheximide chase assay to evaluate the degra-
dation rate of the 1 subunit. As expected, overexpression of
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Hrd1 accelerates the degradation of the 1 subunit, but
repressing Hrd1 activity by overexpressing C291A Hrd1 slows
its degradation (Fig. 4F). We then determined the effect of Hrd1
in ubiquitinating the 1 subunit. Cell ubiquitination assays
showed that knockdown of Hrd1 (Fig. 4G) or overexpression of
C291A Hrd1 (Fig. 4H) decreased the ubiquitinated subunit as
well as the ratio of ubiquitinated to total 1 subunit. Consis-
tently, overexpression of Hrd1 enhanced the ubiquitination of
the 1 subunit (Fig. 4H). The above data (Fig. 4, A–H) unam-
biguously demonstrated that Hrd1 plays an essential role in
ubiquitinating the 1 subunit during its ERAD pathway. As a
result, inhibiting Hrd1 by using siRNA or overexpressing
C291A Hrd1 increased the surface protein level of the 1 sub-
unit, and overexpressing Hrd1 decreased its surface level signif-
icantly (Fig. 4, A and D).
VCP, an AAA ATPase, plays an essential role in extracting
polyubiquitinated substrates from the ER to the cytosol and
driving this retrotranslocation process (62, 63). Recently, we
showed that VCP binds the WT 1 subunit and that inhibiting
VCP increased its protein level, supporting VCP’s critical role
in degrading the 1 subunit (15). Because Grp94 acts early in
the ERAD recognition step for the 1 subunit, we expected that
Grp94 functions upstream of Hrd1 and VCP. Indeed, a co-im-
munoprecipitation assay demonstrated that knockdown of
Grp94 significantly decreased the interaction between the 1
subunit and VCP/Hrd1 (Fig. 4I), confirming such a sequential
binding. Moreover, application of eeyarestatin I, a potent VCP
inhibitor (64), increased the interaction between the 1 subunit
and Grp94 (Fig. 3D, 5th lane), further supporting the idea that
Grp94 operates upstream of VCP. In addition, as expected,
treatment with MG-132, a potent proteasome inhibitor, accu-
mulated more 1 subunits in the ER and increased their inter-
action with Grp94 (Fig. 3D, 4th lane).
Inhibiting Grp94 Enhances the Functional Surface Expression
of the Pathogenic 1(A322D) Subunit of GABAA Receptors—
Numerous mutations in GABAA receptors predispose them to
misfolding and excessive ERAD (29). A prototype of such muta-
tions is the A322D mutation in the 1 subunit, causing auto-
somal dominant juvenile myoclonic epilepsy (31). Recently, we
demonstrated that reducing ERAD by inhibiting VCP slows the
degradation of the 1(A322D) subunit and promotes its for-
ward trafficking (15). Because Grp94 acts early in the ERAD
recognition step, which is upstream of VCP (Fig. 4I), we next
evaluated whether inhibiting Grp94 enhances the functional
surface expression of the 1(A322D) subunit. Strikingly,
knockdown of Grp94 (42% knockdown efficiency) significantly
increased the total 1(A322D) protein level 2.4-fold and the cell
surface 1(A322D) protein level 2.8-fold in HEK293 cells
expressing 1(A322D)22 GABAA receptors (Fig. 5A). Nota-
bly, the effect of Grp94 knockdown on the 1 protein level
increase is more dramatic in cells expressing the 1(A322D)
subunit than those expressing the WT 1 subunit (Figs. 1B and
5A), presumably because the 1(A322D) subunit degrades
much faster than the WT 1 subunit. Moreover, modest knock-
down of Grp94 (36% knockdown efficiency) significantly
increased the total 1(A322D) protein level 2.0-fold and the cell
surface 1(A322D) protein level 1.5-fold in human neuronal
SH-SY5Y cells stably overexpressing 1(A322D)22 GABAA
receptors (Fig. 5B). Consistently, application of BNIM (5 
M), a
specific, potent Grp94 inhibitor (37), increased the surface
expression of the 1(A322D) subunit 2.0-fold (Fig. 5C).
To determine whether the increased surface 1(A322D) sub-
units form functional receptors on the plasma membrane, we
performed a whole-cell patch clamping experiment to record
GABA-induced chloride current. To ensure that recording was
done for successfully transfected cells, Grp94 siRNA was co-
transfected with an mCherry plasmid in monoclonal HEK293
cells expressing the 1(A322D) 22 GABAA receptors, and
only mCherry-positive cells were selected for recording. Grp94
knockdown significantly increased the peak GABA-induced
chloride current to 46 pA (Fig. 5D), demonstrating a partial
restoration of function for epilepsy-associated 1(A322D)
GABAA receptors.
Discussion
Fig. 6 illustrates the first ERAD pathway model of the 1
subunit of GABAA receptors. Upon entering the ER, newly syn-
thesized 1 subunits tend to fold with the assistance of BiP (also
FIGURE 4. Hrd1 ubiquitinates the 1 subunit of GABAA receptors. A and B, Hrd1 knockdown increases the total and cell surface protein level of 1 subunit.
HEK293 cells stably expressing 122 GABAA receptors were transfected with non-targeting (NT) control siRNA or siRNA against Hrd1. Forty eight hours
post-siRNA transfection, cells were lysed, and the total cell lysates were subjected to SDS-PAGE and immunoblotting (IB) with mouse anti-1 or rabbit anti-Hrd1
antibodies (n  3). -Actin serves as a total protein loading control. Alternatively, the surface 1 subunits were measured using cell surface protein biotinyla-
tion assay (n  3). The Na/K-ATPase  chain serves as a loading control for biotinylated membrane proteins. Protein band quantifications using ImageJ are
shown in B. C, knocking down gp78 does not change the total protein level of the 1 subunit. HEK293 cells stably expressing 122 receptors were
transfected with non-targeting control siRNA or siRNA against gp78 for 48 h. Then the cell lysates were subjected to SDS-PAGE and Western blotting assay (n 
2). D and E, effect of overexpressing Hrd1 (WT and C291A) on the total and cell surface protein levels of 1 subunits. HEK293 cells stably expressing 122
GABAA receptors were transfected with a GFP control plasmid, a WT Hrd1 plasmid, or a C291A Hrd1 plasmid. Forty eight hours post-transfection, cells were
treated as in A to detect the total and cell surface 1 protein levels (n  3). GFP serves as a negative control. The C291A mutation in Hrd1 has a dominant
negative effect on its E3 ligase activity. Protein band quantifications are shown in E. F, influence of overexpressing Hrd1 (WT and C291A) on the degradation rate
of the 1 subunit determined by CHX chase analysis. HEK293 cells stably expressing 122 GABAA receptors were transfected with a GFP control plasmid, a
WT Hrd1 plasmid, or a C291A Hrd1 plasmid for 48 h and then chased for the indicated time with CHX (100 
g/ml). Cells were lysed and subjected to SDS-PAGE
and immunoblotting analysis (n  3). The degradation kinetics were plotted by quantifying the 1 protein intensity against time after CHX addition on the
bottom panel. G and H, influence of knocking down or overexpressing Hrd1 on the relative ubiquitination level of 1 subunits. HEK293 cells stably expressing
(FLAG-1)22 GABAA receptors were transfected with an HA-tagged ubiquitin plasmid together with non-targeting control siRNA or siRNA against Hrd1 for
48 h (G) or transfected with a HA-tagged ubiquitin plasmid together with a GFP control plasmid, a WT Hrd1 plasmid, or a C291A Hrd1 plasmid for 48 h (H). Then
the total cell lysates were immunoprecipitated with anti-FLAG M2 magnetic beads. The immunoisolated complexes were subjected to SDS-PAGE and Western
blot analysis. Quantification of the ratio of ubiquitin/1 band intensity post-IP, representing relative ubiquitin level of the 1 subunit, is shown on the bottom
(n  3). I, Grp94 knockdown decreases the interaction between VCP or HRD1 and the 1 subunit. HEK293 cells expressing (FLAG-1)22 GABAA receptors
were transfected with non-targeting control siRNA or siRNA against Grp94 for 48 h. Then the total cell lysates were immunoprecipitated for SDS-PAGE and
Western blot analysis. Quantification of the ratio of VCP or HRD1/1 band intensity post-IP is shown on the bottom (n  3). Each data point in B and E–I is
reported as mean 	 S.E. *, p  0.05; **, p  0.01.
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termed Grp78) in a glycan-independent manner and with the
support from calnexin in a glycan-dependent way. BiP is known
to play a role very early in protein biogenesis by binding to the
hydrophobic patches of unfolded proteins in the ER, facilitating
their folding while preventing aggregation (45, 65). Calnexin, a
membrane-bound lectin chaperone, binds monoglucosylated
N-glycans installed on a glycoprotein and facilitates its folding
with the assistance of protein-disulfide isomerases, such as
ERp57 (66). Recently, we demonstrated that both BiP and cal-
nexin facilitate the maturation of WT 1 subunits (40). After
the collaborative operations of BiP and calnexin, if native struc-
tures are obtained, 1 subunits assemble with other subunits,
FIGURE 5. Grp94 inhibition enhances the functional surface expression of the 1(A322D) subunit of GABAA receptors. A and B, Grp94 knockdown
increases the total and cell surface protein levels of 1(A322D) subunits in HEK293 cells (A) and neuronal SH-SY5Y cells (B) (n  3). Cells stably expressing
1(A322D)22 receptors were transfected with non-targeting (NT) control siRNA or siRNA against Grp94 for 48 h before total protein analysis by Western blot
assay and surface protein analysis by a surface biotinylation assay. Protein band quantifications are shown on the bottom. The Na/K-ATPase  chain serves
as a loading control for biotinylated membrane proteins. C, treatment with a Grp94-specific inhibitor BNIM (5 
M, 24 h) increases the surface protein level of the
1(A322D) subunit in HEK293 cells stably expressing 1(A322D)22 receptors according to surface biotinylation analysis (n  3). The chemical structure of
BNIM is shown on top. D, Grp94 knockdown significantly increases the peak amplitude of GABA (3 mM)-induced chloride currents in HEK293 cells expressing
1(A322D)22 GABAA receptors using a whole-cell patch clamp recording. The holding potential was set at 60 mV. Representative traces are shown on the
top panel, and quantification of the peak currents (Imax) is shown on the bottom panel. The number of patches cells in each group is shown at the top of the bar.
Each data point is reported as mean 	 S.E. *, p  0.05; **, p  0.01.
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such as 2 subunits and 2 subunits, to form a pentamer on the
ER membrane. This pentamer traffics efficiently to the plasma
membrane in a fully functional state. However, if 1 subunits
misfold, Grp94 recognizes their non-native states in the ER
lumen. OS-9 acts downstream of Grp94 to further recognize
the misfolded subunits in a glycan-dependent manner. Grp94
and OS-9 deliver misfolded 1 subunits to Hrd1, which ubiq-
uitinates them. VCP facilities the dislocation of the 1 subunits
from the ER member to the cytosol, where they will be targeted
to the 26S proteasome for degradation.
Many important questions remain to be answered for the
ERAD pathway of the 1 subunit. E3 ligases play a central role
in organizing the ERAD machinery. There are over 500 ubiqui-
tin E3 ligases in mammals. It is believed that one protein uses
only a subset of those E3 ligases. What other E3 ligases play an
important role in the ubiquitination of the 1 subunits?
Recently, it was reported that ring finger protein 34 (RNF34)
promotes the degradation of the 2 subunit by ubiquitinating
them (67). Furthermore, our recent proteomics study identified
several E3 ligases that interact with the 	1 subunit, such as
HUWE1 and UBR5 (68). It will be of great interest to determine
whether these E3 ligases complement the function of Hrd1 in
ubiquitinating the 1 subunits. In addition, presumably Grp94
and OS-9 act on the misfolded domains of the 1 subunit in the
ER lumen. Whether and how the transmembrane domains of
the 1 subunit contribute to the ERAD recognition steps
remain to be determined. Beyond the ERAD factors that were
identified here, we still need to decipher the role of many
known ERAD factors in the context of degrading the 1 sub-
unit, such as EDEM and Derlin family proteins. Therefore, sub-
stantial further studies need to be done to fully understand
ERAD of the 1 subunit. Nonetheless, our report represents a
significant progress toward that end.
We clarified that Grp94 promotes the ERAD of the 1 sub-
units of GABAA receptors. Unlike its cytosolic Hsp90 family
members, Grp94 only has a few known client proteins or sub-
strates in the ER, and the exact function and mechanism of
Grp94 on the folding or ERAD of its substrates remains to be
established (52). The effect of Grp94 on the GABAA receptor
ERAD does not depend on whether the depletion of Grp94 is
short term or long term, which is different from that on the null
Hong Kong variant of 1-antitrypsin (NHK). Previously, it was
reported that transient knockdown of Grp94 delayed the deg-
radation and increased the steady state level of NHK (42, 43),
whereas stably depleting Grp94 had no apparent effect (54).
Up-regulation of BiP by transient knockdown of Grp94 might
contribute to such a discrepancy on NHK; alternatively, long
term depletion of Grp94 might result in cell adaption for the
altered proteostasis network. A similar discrepancy was
reported between short term or long term depletion of gp78;
transient knockdown of gp78 using siRNA attenuated the deg-
radation of a model ERAD substrate, MHC(1–147), whereas
permanent depletion of gp78 using CRISPR cells had no effect
(60). It was proposed that cells can adapt to compensate for the
function of gp78 during the permanent gp78 inactivation pro-
cess (60). Therefore, one possibility is that if an ERAD factor is
essential for the disposal of one substrate, cells cannot adapt to
the loss of that ERAD factor; if not essential, cells can adjust by
adapting the proteostasis network. Our results supported that
the ERAD of GABAA receptors critically depends on Grp94,
adding GABAA receptor subunits to the very limited pool of
Grp94 substrates. Because the -sheet-rich 1 subunit has dis-
tinct structures compared with other known Grp94 substrates,
how this subunit is recognized by Grp94 remains to be investi-
gated. Grp94 inhibition stabilizes 1 subunits and enhances
their functional surface expression. Our results strongly sup-
port that Grp94 regulates GABAA receptor function directly
because Grp94 binds the 1 subunit in vitro and in vivo. Grp94
inhibition has a much greater effect on 1(A322D) subunits
than WT 1 subunits. Therefore, specific Grp94 inhibition pro-
vides a promising way to enhance the function of misfolding-
prone 1 subunits, as a therapeutic strategy to ameliorate idio-
pathic epilepsy. To achieve further specificity, it is also of
interest to disrupt the direct interaction between Grp94 and 1
subunits.
For fast-degraded ERAD substrates, it is desirable to enhance
folding as well as reducing ERAD to achieve substantial func-
tional rescue. Recently, we identified different classes of small
molecule proteostasis regulators that enhance the folding and
trafficking and thus the function of epilepsy-associated mutant
GABAA receptors (40, 69). Suberanilohydroxamic acid
increases BiP protein level and the interaction between cal-
nexin and the 1(A322D) subunit, which promotes the func-
tional cell surface expression of this mutant subunit (40). Vera-
pamil, an L-type Ca2 channel blocker, enhances the plasma
membrane trafficking of the 1(D219N) subunit by promoting
calnexin-assisted folding and inter-subunit assembly between
1(D219N) subunit and 2 subunit (69). In addition, pharma-
cological chaperones, which are small molecules that directly
bind their target protein, stabilize it and enhance its forward
trafficking (70). Both proteostasis regulators and pharmacolog-
FIGURE 6. Proposed ERAD model of the 1 subunit of GABAA receptors.
The 1 subunits are co-translationally translocated to the ER membrane. They
tend to fold with the assistance of BiP in a glycan-independent manner and
calnexin (CNX) in a glycan-dependent manner. Properly folded 1 subunits
assemble with other subunits to form a heteropentamer on the ER membrane
for trafficking to the plasma membrane. However, if 1 subunits misfold,
Grp94 recognizes the non-native states in the ER lumen. In the ER lumen, OS-9
further recognizes the misfolded subunits in a glycan-dependent manner
and delivers them to Hrd1. Hrd1 ubiquitinates 1 subunits and translocates
them from the ER member to the cytosol with the assistance of VCP. Then
misfolded 1 subunits are targeted to the 26S proteasome for degradation.
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ical chaperones are expected to yield an additive/synergistic
effect with ERAD inhibitors to enhance the function of GABAA
receptors. Indeed, recently, we revealed that combining subera-
nilohydroxamic acid treatment with eeyarestatin I, a VCP
inhibitor, additively restored the functional cell surface expres-
sion of the 1(A322D) subunit, providing a proof-of-principle
case (15). The elucidation of the ERAD pathway of GABAA
receptors allows the development of a more effective combina-
tion therapy to restore the function of disease-causing GABAA
receptors.
GABAA receptors are within the superfamily of Cys-loop
receptors, which contain important neuroreceptors, including
nicotinic acetylcholine receptors, serotonin type 3 receptors,
and glycine receptors (2, 11). They are responsible for fast excit-
atory and inhibitory transmission in nervous systems. Because
they share common structural characteristics, much of our
knowledge gained on the folding, assembly, and degradation of
GABAA receptors could be extrapolated to the whole class of
Cys loop receptors.
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